# Eucalyptus Oil as Adjuvant Therapy for Coronavirus Disease 19 (COVID-19)

> **NCT05398965** · PHASE2 · COMPLETED · sponsor: **Hasanuddin University** · enrollment: 54 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Eucalyptus Oil
- **DRUG:** Standard COVID medication

## Key facts

- **NCT ID:** NCT05398965
- **Lead sponsor:** Hasanuddin University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-18
- **Primary completion:** 2021-01-28
- **Final completion:** 2022-03-01
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2022-06-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05398965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05398965, "Eucalyptus Oil as Adjuvant Therapy for Coronavirus Disease 19 (COVID-19)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05398965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*